1.Drug-induced bile duct injury: progress and challenges.
Chinese Journal of Hepatology 2023;31(4):339-344
Drug-induced bile duct injury is a specific kind of drug-induced liver injury that has two main pathological types, namely ductopenia, or vanishing bile duct syndrome, and secondary sclerosing cholangitis. However, in recent years, the reports of new drugs that cause bile duct injury have been constantly increasing, and these drugs have different clinicopathological features and a novel pathogenesis. Therefore, this paper summarizes and analyzes the progress and challenges in the etiology, pathogenesis, diagnosis and treatment, and other aspects of drug-induced bile duct injury.
Humans
;
Cholestasis/chemically induced*
;
Cholangitis, Sclerosing/diagnosis*
;
Chemical and Drug Induced Liver Injury/pathology*
;
Bile Ducts/pathology*
2.Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile.
Se Joon LEE ; Jun Sik CHO ; Jun Pyo CHUNG ; Kwan Sik LEE ; Jae Bock CHUNG ; Sang In LEE ; Young Myoung MOON ; Jin Kyung KANG ; Sung Won KWON ; Hoon Sang CHI ; Jong Rak CHOI ; Kyung Soon SONG
Yonsei Medical Journal 2000;41(1):119-122
Fibrinolytic properties have been detected in animal and human gallbladder (GB) bile. Plasminogen activator inhibitor-1 (PAI-1) has been reported in greater concentration in GB stone bile and may be a nucleating factor in the pathogenesis of GB stone formation. It is unknown whether or not human choledochal bile has similar properties, which could have a role in choledocholithiasis. The aims of this study were to determine the presence of fibrinolytic properties of human choledochal bile and to compare those properties among normal, acalculous, and calculous-infected choledochal bile. Tissue plasminogen activator (t-PA) and PAI-1 of choledochal bile were measured by enzyme linked immunosorbent assay in patients with cholangitis due to acalculous bile duct obstructions (n = 9), choledocholithiasis with cholangitis (n = 20), and normal bile (n = 7). The t-PA concentration of choledochal bile was no different among the three groups (acalculous-infected bile, median 4.61 ng/ml, and calculous-infected bile, 4.61 ng/ml, versus normal bile, 7.33 ng/ml). PAI-1 was detected in choledochal bile in significantly greater concentrations in patients with acalculous cholangitis due to bile duct obstructions and choledocholithiasis with cholangitis (acalculous-infected bile, median 0.36 ng/ml, and calculous-infected bile, 0.1 ng/ml, versus normal bile, 0.02 ng/ml, p < 0.05), but the bile concentration of PAI-1 was no different between the acalculous and calculous-infected choledochal bile. Human choledochal bile possesses t-PA and PAI-1. PAI-1 was present in greater concentrations in both acalculous and calculous-infected choledochal bile. Increased levels of PAI-1 may be an epiphenomenon of cholangitis rather than a factor in the pathogenesis of choledocholithiasis.
Aged
;
Bile/microbiology
;
Bile/chemistry*
;
Cholangitis/microbiology
;
Cholangitis/metabolism
;
Cholangitis/etiology
;
Cholangitis/chemically induced
;
Cholestasis/metabolism
;
Cholestasis/complications
;
Common Bile Duct/metabolism*
;
Common Bile Duct Calculi/metabolism
;
Common Bile Duct Calculi/complications
;
Female
;
Human
;
Male
;
Middle Age
;
Plasminogen Activator Inhibitor 1/analysis*
;
Tissue Plasminogen Activator/analysis*